PMID- 23972711
OWN - NLM
STAT- MEDLINE
DCOM- 20131029
LR  - 20211203
IS  - 1532-8708 (Electronic)
IS  - 0093-7754 (Linking)
VI  - 40
IP  - 4
DP  - 2013 Aug
TI  - Combination therapy in metastatic renal cell cancer.
PG  - 472-81
LID - S0093-7754(13)00085-7 [pii]
LID - 10.1053/j.seminoncol.2013.05.010 [doi]
AB  - The standard strategy in metastatic renal cell carcinoma (mRCC) is to use 
      sequential treatment. Different pathways are known to be involved in the 
      pathogenesis of mRCC and in the development of resistance to targeted drugs. 
      Combinations of targeted drugs could theoretically achieve better inhibition of a 
      given pathway, inhibition of different pathways, or inhibition of a pathway 
      involved in the resistance to a given drug. However, there is as yet no clear 
      evidence that combination therapy is of clinical benefit and excess toxicity has 
      been observed. In mRCC the majority of studies have explored combinations of 
      vascular endothelial growth factor (VEGF) inhibitors and mammalian target of 
      rapamycin (mTOR) inhibitors. A new generation of VEGF tyrosine kinase inhibitors 
      (TKIs) seems to be more tolerable, and therefore potentially easier to combine 
      with other agents. Trials with PI3K/akt/mTORC1/2 inhibitor combinations and with 
      other new targeted drugs are also ongoing.
CI  - (c) 2013 Elsevier Inc. All rights reserved.
FAU - Ravaud, Alain
AU  - Ravaud A
AD  - Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France. 
      alain.ravaud@chu-bordeaux.fr
FAU - Gross-Goupil, Marine
AU  - Gross-Goupil M
FAU - Bellmunt, Joaquim
AU  - Bellmunt J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Semin Oncol
JT  - Seminars in oncology
JID - 0420432
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy/secondary
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/pathology
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
EDAT- 2013/08/27 06:00
MHDA- 2013/10/30 06:00
CRDT- 2013/08/27 06:00
PHST- 2013/08/27 06:00 [entrez]
PHST- 2013/08/27 06:00 [pubmed]
PHST- 2013/10/30 06:00 [medline]
AID - S0093-7754(13)00085-7 [pii]
AID - 10.1053/j.seminoncol.2013.05.010 [doi]
PST - ppublish
SO  - Semin Oncol. 2013 Aug;40(4):472-81. doi: 10.1053/j.seminoncol.2013.05.010.